Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
Your view on KPTI
Overview
What the company does, where it operates, and who runs it.
About Karyopharm Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard A. Paulson
- Headquarters
- 85 Wells Avenue, Newton, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard A. Paulson
- Headquarters
- 85 Wells Avenue, Newton, MA, US
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins.
The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Karyopharm Therapeutics Inc., and the rating behind it. KPTI last traded at $1.61; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Karyopharm Therapeutics Inc.. Starting points for Karyopharm Therapeutics Inc.: EPS -$7.77, beta 0.95 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Karyopharm Therapeutics Inc.. Karyopharm Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Karyopharm Therapeutics Inc.. Trailing twelve-month EPS for Karyopharm Therapeutics Inc. stands at -$7.77. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Karyopharm Therapeutics Inc.. Karyopharm Therapeutics Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Karyopharm Therapeutics Inc. valued side by side against its closest peers. Karyopharm Therapeutics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Karyopharm Therapeutics Inc., and how their positions are changing. At a $36.5M market value, institutional positions materially move Karyopharm Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Karyopharm Therapeutics Inc. executives and directors. Shares of Karyopharm Therapeutics Inc. have traded between $3.51 and $13.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Karyopharm Therapeutics Inc.. Karyopharm Therapeutics Inc. is a $36.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Karyopharm Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Karyopharm Therapeutics Inc.. Coverage tracks Karyopharm Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.